User login
Article Type
Changed
Thu, 12/15/2022 - 17:59
Display Headline
Encouraging data on immunotherapy, cardiotoxicity, and DFS
The immunologic checkpoint inhibitors avelumab and pemrolizomab show promise in patients with metastatic breast cancer; a trastuzumab-based, nonanthracycline regimen yields cardiac safety benefits in early HER2-positive disease; and the oral tyrosine kinase inhibitor neratinib delivers consistent disease-free survival at 3 years: Bruce Jancin and Susan London report from the 2015 annual meeting of the San Antonio Breast Cancer Symposium.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 14(2)
Topics
Page Number
85-88
Legacy Keywords
avelumab, metastatic breast cancer, programmed death-ligand 1, PD-L1, immune checkpoint inhibitor, triple-negative breast cancer, TNBC, pembrolizumab, estrogen receptor-positive, human epidermal growth factor receptor 2, HER2, trastuzumab, cardiac toxicity, neratinib, disease-free survival, DFS
Sections
Article PDF
Article PDF
The immunologic checkpoint inhibitors avelumab and pemrolizomab show promise in patients with metastatic breast cancer; a trastuzumab-based, nonanthracycline regimen yields cardiac safety benefits in early HER2-positive disease; and the oral tyrosine kinase inhibitor neratinib delivers consistent disease-free survival at 3 years: Bruce Jancin and Susan London report from the 2015 annual meeting of the San Antonio Breast Cancer Symposium.
Click on the PDF icon at the top of this introduction to read the full article.
The immunologic checkpoint inhibitors avelumab and pemrolizomab show promise in patients with metastatic breast cancer; a trastuzumab-based, nonanthracycline regimen yields cardiac safety benefits in early HER2-positive disease; and the oral tyrosine kinase inhibitor neratinib delivers consistent disease-free survival at 3 years: Bruce Jancin and Susan London report from the 2015 annual meeting of the San Antonio Breast Cancer Symposium.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 14(2)
Issue
The Journal of Community and Supportive Oncology - 14(2)
Page Number
85-88
Page Number
85-88
Topics
Article Type
Display Headline
Encouraging data on immunotherapy, cardiotoxicity, and DFS
Display Headline
Encouraging data on immunotherapy, cardiotoxicity, and DFS
Legacy Keywords
avelumab, metastatic breast cancer, programmed death-ligand 1, PD-L1, immune checkpoint inhibitor, triple-negative breast cancer, TNBC, pembrolizumab, estrogen receptor-positive, human epidermal growth factor receptor 2, HER2, trastuzumab, cardiac toxicity, neratinib, disease-free survival, DFS
Legacy Keywords
avelumab, metastatic breast cancer, programmed death-ligand 1, PD-L1, immune checkpoint inhibitor, triple-negative breast cancer, TNBC, pembrolizumab, estrogen receptor-positive, human epidermal growth factor receptor 2, HER2, trastuzumab, cardiac toxicity, neratinib, disease-free survival, DFS
Sections
Citation Override
JCSO 2016;14:85-88
Disallow All Ads
Alternative CME
Article PDF Media
Document